evid
suggest
cancer
patient
higher
risk
death
therefor
riskbenefit
ratio
number
palli
neo
adjuv
treatment
reconsid
pandem
durat
period
detail
risk
remain
determin
number
factor
age
comorbid
also
influenc
risk
addit
visit
hospit
associ
specif
treatment
advic
set
give
suggest
period
risk
consid
rigid
guidelin
tradit
sens
rather
pragmat
perspect
riskbenefit
ratio
specif
clinic
scenario
addit
advic
appli
patient
number
variabl
includ
stage
pandem
local
health
care
capac
risk
infect
individu
statu
cancer
comorbid
age
detail
treatment
focu
last
factor
minimis
potenti
exposur
reduc
visit
hospit
particularli
intraven
inpati
therapi
relev
particularli
import
initi
phase
pandem
incid
increas
exponenti
upcom
pressur
health
care
resourc
unknown
predict
statu
health
care
facil
abil
deliv
system
therapi
futur
requir
consider
factor
vari
geograph
region
number
factor
requir
consider
regimen
clear
surviv
advantag
prioritis
cur
treatment
remain
mandatori
other
requir
consider
riskbenefit
ratio
treatment
shown
palli
effect
patient
symptomat
requir
care
discuss
delay
start
therapi
period
uncertainti
difficulti
appropri
measur
mani
therapi
urolog
cancer
cur
treatment
use
growth
factor
prophylact
antibiot
consid
avoid
hospitalis
palli
treatment
given
dose
intens
avoid
febril
neutropenia
recommend
suboptim
dose
neutropenia
occur
dose
need
reduc
episod
prophylact
antibiot
recommend
appropri
immunosuppress
agent
steroid
avoid
reduc
antiemesi
possibl
prolong
steroid
treatment
prostat
cancer
requir
consider
agent
reduc
incid
skeletalrel
event
bisphosphon
probabl
best
postpon
administr
therapi
involv
potenti
exposur
tabl
adjuv
neoadjuv
treatment
requir
particular
attent
riskbenefit
ratio
may
favour
give
therapi
surviv
benefit
modest
unproven
periop
therapi
urotheli
cancer
convers
neoadjuv
therapi
may
attract
delay
need
surgeryradiotherapi
case
servic
interrupt
aspect
clinic
trial
may
appropri
pandem
recruit
clinic
trial
requir
care
consider
halt
recruit
cancer
trial
divert
resourc
fight
pandem
may
appropri
landscap
chang
risk
infect
alter
known
prevent
treat
addit
treatment
antivir
e
u
r
p
e
n
u
r
l
g
x
x
x
x
x
x
x
x
x
v
l
b
l
e
w
w
w
c
e
n
c
e
r
e
c
c
j
u
r
n
l
h
e
p
g
e
w
w
w
e
u
r
p
e
n
u
r
l
g
c
agent
may
improv
outcom
hope
advic
quickli
becom
redund
oral
vegf
therapi
rather
iv
immun
therapi
convent
dose
rather
highdos
therapi
ici
rather
ctx
frontlin
metastat
diseas
ar
androgen
receptor
ctx
chemotherapi
ici
immun
checkpoint
inhibitor
imdc
intern
metastat
renal
cell
carcinoma
databas
consortium
iv
intraven
oral
vegftarget
therapi
rather
iv
ici
may
attract
requir
less
health
care
interact
resourc
b
younger
cancer
patient
without
comorbid
may
lower
risk
consid
c
neoadjuv
chemotherapi
may
help
bridg
time
surgeri
case
elect
surgeri
possibl
regimen
longer
interv
nivolumab
pembrolizumab
use
possibl
e
palli
ctx
test
specif
number
cycl
risk
associ
stop
assess
principl
delay
chemotherapi
subgroup
prostat
urotheli
cancer
patient
continu
ctx
full
number
cycl
may
associ
risk
benefit
patient
need
particip
discuss
f
assum
similar
efficaci
regimen
e
u
r
p
e
n
u
r
l
g
x
x
x
x
x
x
x
x
x
